Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ABCL

ABCL - AbCellera Biologics Inc Stock Price, Fair Value and News

4.74USD-0.57 (-10.73%)Delayed as of 21 Feb 2024, 01:01 pm ET
Watchlist

Market Summary

USD4.74-0.57
Delayedas of 21 Feb 2024, 01:01 pm
-10.73%

ABCL Stock Price

View Fullscreen

ABCL RSI Chart

ABCL Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-11.93

Price/Sales (Trailing)

3.05

EV/EBITDA

-9.43

Price/Free Cashflow

-22.59

ABCL Price/Sales (Trailing)

ABCL Profitability

EBT Margin

-32.31%

Return on Equity

-10.92%

Return on Assets

-8.54%

Free Cashflow Yield

-4.43%

ABCL Fundamentals

ABCL Revenue

Revenue (TTM)

485.4M

Rev. Growth (Yr)

-93.49%

Rev. Growth (Qtr)

-34.38%

ABCL Earnings

Earnings (TTM)

-129.1M

Earnings Growth (Yr)

-207.46%

Earnings Growth (Qtr)

6.28%

Breaking Down ABCL Revenue

52 Week Range

4.348.83
(Low)(High)

Last 7 days

4.5%

Last 30 days

-0.9%

Last 90 days

19.5%

Trailing 12 Months

-45.7%

How does ABCL drawdown profile look like?

ABCL Financial Health

Current Ratio

8.34

ABCL Investor Care

Shares Dilution (1Y)

1.42%

Diluted EPS (TTM)

-0.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
2022489.0M507.3M603.2M485.4M
2021431.2M447.7M443.8M375.2M
202067.0M122.4M177.8M233.2M
201900011.6M

Tracking the Latest Insider Buys and Sells of AbCellera Biologics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 19, 2023
thermopylae holdings ltd.
gifted
-
-
-210,000
-
Nov 23, 2023
hansen carl l. g.
acquired
151,538
2.7
56,125
chief executive officer
Nov 08, 2023
montalbano john s.
bought
44,600
4.46
10,000
-
Nov 06, 2023
montalbano john s.
bought
92,800
4.64
20,000
-
Sep 22, 2023
hayden michael r
bought
98,200
4.91
20,000
-
Sep 12, 2023
lecault veronique
bought
103,800
5.19
20,000
chief operating officer
Aug 24, 2023
hansen carl l. g.
acquired
151,538
2.7
56,125
chief executive officer
Aug 08, 2023
hayden michael r
bought
177,000
5.9
30,000
-
May 26, 2023
booth andrew
bought
99,325
6.85
14,500
chief financial officer
May 26, 2023
hansen carl l. g.
acquired
151,538
2.7
56,125
chief executive officer

1–10 of 50

Which funds bought or sold ABCL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
added
139
1,330,000
2,002,000
0.17%
Feb 16, 2024
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
unchanged
-
2,553
13,133
-%
Feb 15, 2024
Virtus ETF Advisers LLC
added
26.22
34,894
96,465
0.06%
Feb 15, 2024
GTS SECURITIES LLC
added
96.67
107,023
181,281
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
57,169
57,169
-%
Feb 15, 2024
BARCLAYS PLC
added
474
592,000
689,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
117
874,419
1,390,040
-%
Feb 14, 2024
Voya Investment Management LLC
unchanged
-
11,792,800
60,664,100
0.07%
Feb 14, 2024
ORBIMED ADVISORS LLC
unchanged
-
4,640,650
23,872,200
0.48%
Feb 14, 2024
VANGUARD GROUP INC
new
-
74,870
74,870
-%

1–10 of 41

Are Funds Buying or Selling ABCL?

Are funds buying ABCL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ABCL
No. of Funds

Unveiling AbCellera Biologics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
baker bros. advisors lp
7.9%
22,909,753
SC 13G
Feb 13, 2024
hansen carl l. g.
20.6%
60,740,524
SC 13G/A
Jan 29, 2024
baillie gifford & co
8.29%
24,044,796
SC 13G/A
Apr 24, 2023
thiel peter
4.99%
14,360,427
SC 13D/A
Feb 13, 2023
capital world investors
3.3%
9,327,493
SC 13G/A
Feb 06, 2023
hansen carl l. g.
20.4%
58,993,307
SC 13G/A
Jan 18, 2023
baillie gifford & co
6.88%
19,696,735
SC 13G
Feb 14, 2022
dcvc bio, l.p.
2.6%
7,305,761
SC 13G/A
Feb 14, 2022
viking global investors lp
0.0%
0
SC 13G/A
Feb 11, 2022
capital world investors
7.8%
22,051,703
SC 13G

Recent SEC filings of AbCellera Biologics Inc

View All Filings
Date Filed Form Type Document
Feb 20, 2024
S-8
Employee Benefits Plan
Feb 20, 2024
8-K
Current Report
Feb 20, 2024
10-K
Annual Report
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Jan 29, 2024
SC 13G/A
Major Ownership Report
Jan 16, 2024
4
Insider Trading
Jan 16, 2024
4
Insider Trading
Jan 16, 2024
4
Insider Trading
Jan 16, 2024
4
Insider Trading

Peers (Alternatives to AbCellera Biologics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.2B
9.1B
-16.59% -47.80%
-9.57
3.64
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
18.9B
1.8B
-23.99% -31.71%
-42.82
10.31
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.61
7.23
15.05% 75.21%
13.2B
3.7B
-7.62% -26.87%
22.1
3.57
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.27
29.46
141.38% 4.43%
6.3B
107.9M
-3.85% 226.12%
-10.03
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-19.02
17.18
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.2
15.04
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.7
4.22
81.69% -7.29%
490.6M
1.0B
-9.17% -57.89%
-0.89
0.47
-43.15% 58.48%
185.9M
4.9M
-14.18% -58.18%
-1.13
38.02
-57.57% 50.48%
103.1M
881.7K
289.54% 381.25%
-2.17
112.79
-77.61% -13.74%
4.4M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

AbCellera Biologics Inc News

Latest updates
MarketBeat3 hours ago

AbCellera Biologics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In null)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Revenue-34.4%7.0010.0016.0022.0010146.003171395.0028.002032089.0011.005.00-
Operating Expenses0.1%61.0061.0077.0059.0064.0054.0092.0058.0034.0035.0045.0047.0011.0012.007.00-
  S&GA Expenses-9.7%3.004.004.003.003.003.002.002.001.001.003.002.001.001.000.00-
  R&D Expenses4.0%38.0036.0053.0028.0027.0027.0026.0017.0017.0015.0012.009.007.009.004.00-
EBITDA Margin-142.7%-0.30*-0.12*-0.06*0.51*0.60*0.57*0.60*0.60*0.68*0.72*0.76*0.69*0.00*---
Income Taxes-42.7%-10.67-7.48-8.04-1.5220.00-0.1062.0025.00-3.590.0044.00-----
Earnings Before Taxes-3.3%-39.28-38.00-48.15-31.4147.00-6.8923185.00-24.97-2.07161156-2.697.00-2.09-
EBT Margin-121.0%-0.32*-0.15*-0.08*0.49*0.59*0.56*0.59*0.58*0.65*0.70*0.75*0.68*-0.01*---
Net Income6.3%-28.61-30.53-40.11-29.8927.00-6.7816960.00-21.38-2.321172.00-2.697.00-2.09-
Net Income Margin-74.7%-0.27*-0.15*-0.10*0.33*0.41*0.39*0.42*0.41*0.21*0.25*0.29*0.02*-0.01*---
Free Cashflow-180.0%-20.44-7.30-59.0519.00-13924286.00-26.14-14.51121106-0.22-7.69---
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets-1.6%1,5121,5371,4981,5411,5521,5941,5921,3191,1731,1521,1291,006
  Current Assets-1.2%9209319411,0251,0461,1441,174930804864908813
    Cash Equivalents-4.1%1721801933873978165718.00518793686594
  Net PPE6.8%27726023321720114912211292.0087.0035.0018.00
  Goodwill0%48.0048.0048.0048.0048.0048.0048.0048.0049.0032.0032.0032.00
Liabilities-3.8%329342289308302381385293219184171175
  Current Liabilities-7.3%11011990.0011810622121312150.0070.0088.00103
Shareholder's Equity-1.0%1,1831,1951,2091,2331,2501,2131,2081,026953968957831
  Retained Earnings-8.0%327356386426456429436268208229231114
  Additional Paid-In Capital13.4%10996.0082.0074.0064.0056.0045.0035.0027.0022.0015.006.00
Shares Outstanding0%287287287290285284284283274272270159
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Cashflow From Operations-100.5%-10619,903-44,06330,912-126,786273,015100,219-16,712-5,932157,683109,5451,278-3,80125,977-764-
  Share Based Compensation-3.3%15,86216,39915,47413,32311,75412,11312,2919,0387,7088,4735,4274,6221,9326061,237-
Cashflow From Investing62.8%-12,786-34,390-149,609-17,063-281,994-27,197-26,371-1,149-269,626-45,633-15,839-108,182-3,885-2,130-5,583-
Cashflow From Financing1482.3%6,630419-458349-19.001,173-3,1311,834898-5,075-1,543609,939-14,37034687,738-

ABCL Income Statement

2023-09-30
Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:    
Total revenue$ 6,599$ 101,383$ 28,846$ 463,879
Operating expenses:    
Royalty fees015,035064,882
Research and development[1]37,91726,582127,03679,634
Sales and marketing[1]3,4683,08911,0808,579
General and administrative[1]14,36913,79245,02542,470
Depreciation and amortization5,7355,15016,85914,025
Total operating expenses61,48963,648200,000209,590
Income (loss) from operations(54,890)37,735(171,154)254,289
Other (income) expense    
Interest (income)(10,740)(5,556)(31,278)(7,609)
Grants and incentives(2,828)(2,150)(10,779)(8,879)
Other(2,046)(1,146)(3,670)266
Total other (income)(15,614)(8,852)(45,727)(16,222)
Net earnings (loss) before income tax(39,276)46,587(125,427)270,511
Income tax (recovery) expense(10,666)19,963(26,179)82,099
Net earnings (loss)(28,610)26,624(99,248)188,412
Foreign currency translation adjustment439(1,293)(69)(997)
Comprehensive income (loss)$ (28,171)$ 25,331$ (99,317)$ 187,415
Net earnings (loss) per share attributable to common shareholders    
Basic (in dollars per share)$ (0.10)$ 0.09$ (0.34)$ 0.66
Diluted (in dollars per share)$ (0.10)$ 0.08$ (0.34)$ 0.60
Weighted-average common shares outstanding    
Basic (in shares)289,496,841285,322,719288,750,387284,639,599
Diluted (in shares)289,496,841315,818,163288,750,387314,183,994
Research fees    
Revenue:    
Total revenue$ 6,413$ 7,508$ 26,812$ 29,378
Licensing revenue    
Revenue:    
Total revenue186154784531
Milestone payments    
Revenue:    
Total revenue04001,250400
Royalty revenue    
Revenue:    
Total revenue$ 0$ 93,321$ 0$ 433,570
[1]Exclusive of depreciation and amortization

ABCL Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 172,422$ 386,535
Marketable securities613,418499,950
Total cash, cash equivalents, and marketable securities785,840886,485
Accounts and accrued receivable37,44638,593
Restricted cash25,00025,000
Other current assets71,23275,413
Total current assets919,5181,025,491
Long-term assets:  
Property and equipment, net277,209217,255
Intangible assets, net124,076131,502
Goodwill47,80647,806
Investments in and loans to equity accounted investees62,88772,522
Other long-term assets80,69446,331
Total long-term assets592,672515,416
Total assets1,512,1901,540,907
Current liabilities:  
Accounts payable and other liabilities35,70833,150
Contingent consideration payable53,92944,211
Accrued royalties payable3,09419,347
Deferred revenue17,50821,612
Total current liabilities110,239118,320
Long-term liabilities:  
Operating lease liability75,18576,675
Deferred revenue16,38219,516
Deferred government contributions84,07240,801
Contingent consideration payable5,30816,054
Deferred tax liability33,17833,178
Other long-term liabilities5,0513,086
Total long-term liabilities219,176189,310
Total liabilities329,415307,630
Commitments and contingencies
Shareholders' equity:  
Common shares: no par value, unlimited authorized shares at December 31, 2022 and September 30, 2023: 286,851,595 and 289,777,654 shares issued and outstanding at December 31, 2022 and September 30, 2023, respectively747,914734,365
Additional paid-in capital109,38474,118
Accumulated other comprehensive (loss)(1,460)(1,391)
Accumulated earnings326,937426,185
Total shareholders' equity1,182,7751,233,277
Total liabilities and shareholders' equity$ 1,512,190$ 1,540,907
ABCL
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
 CEO
 WEBSITEwww.abcellera.com
 EMPLOYEES590

AbCellera Biologics Inc Frequently Asked Questions


What is the ticker symbol for AbCellera Biologics Inc? What does ABCL stand for in stocks?

ABCL is the stock ticker symbol of AbCellera Biologics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AbCellera Biologics Inc (ABCL)?

As of Tue Feb 20 2024, market cap of AbCellera Biologics Inc is 1.54 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABCL stock?

You can check ABCL's fair value in chart for subscribers.

What is the fair value of ABCL stock?

You can check ABCL's fair value in chart for subscribers. The fair value of AbCellera Biologics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AbCellera Biologics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABCL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AbCellera Biologics Inc a good stock to buy?

The fair value guage provides a quick view whether ABCL is over valued or under valued. Whether AbCellera Biologics Inc is cheap or expensive depends on the assumptions which impact AbCellera Biologics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABCL.

What is AbCellera Biologics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 20 2024, ABCL's PE ratio (Price to Earnings) is -11.93 and Price to Sales (PS) ratio is 3.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABCL PE ratio will change depending on the future growth rate expectations of investors.